ES2136338T3 - Derivados de camptotecina y su utilizacion como agente antitumoral. - Google Patents

Derivados de camptotecina y su utilizacion como agente antitumoral.

Info

Publication number
ES2136338T3
ES2136338T3 ES96105661T ES96105661T ES2136338T3 ES 2136338 T3 ES2136338 T3 ES 2136338T3 ES 96105661 T ES96105661 T ES 96105661T ES 96105661 T ES96105661 T ES 96105661T ES 2136338 T3 ES2136338 T3 ES 2136338T3
Authority
ES
Spain
Prior art keywords
compound
camptotecina
derivatives
antitumoral agent
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96105661T
Other languages
English (en)
Inventor
Shinji Kamihara
Kazuaki Kanai
Shigeru Noguchi
Hirofumi Terasawa
Hiroaki Kitaoka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Pharmaceutical Co Ltd
Yakult Honsha Co Ltd
Original Assignee
Daiichi Pharmaceutical Co Ltd
Yakult Honsha Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Pharmaceutical Co Ltd, Yakult Honsha Co Ltd filed Critical Daiichi Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2136338T3 publication Critical patent/ES2136338T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE PRESENTA UN PROCESO PARA LA PREPARACION DE UN COMPUESTO REPRESENTADO POR LA FORMULA (1), QUE INCLUYE EL TRATAMIENTO DE UN COMPUESTO REPRESENTADO POR LA FORMULA (2) CON UN ACIDO METANO SULFONICO Y SOMETER DESPUES AL COMPUESTO ASI TRATADO A LA RECRISTALIZACION; Y COMPUESTO (1) ASI OBTENIDO. ESTE COMPUESTO (1) NO TIENE HIGROSCOPICIDAD, ES EXCELENTE EN SU FILTRABILIDAD Y SOLUBILIDAD Y ES DE FACIL MANEJO. ADEMAS, DE ACUERDO CON EL PROCESO DE PREPARACION DE LA PRESENTE INVENCION, SE PUEDE CONVERTIR UN ISOMERO INNECESARIO EN EL ISOMERO OBJETIVO, PUDIENDOSE REALIZAR FACILMENTE UNA SEPARACION DEL ISOMERO OBJETIVO.
ES96105661T 1995-04-10 1996-04-10 Derivados de camptotecina y su utilizacion como agente antitumoral. Expired - Lifetime ES2136338T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP8371795 1995-04-10

Publications (1)

Publication Number Publication Date
ES2136338T3 true ES2136338T3 (es) 1999-11-16

Family

ID=13810270

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96105661T Expired - Lifetime ES2136338T3 (es) 1995-04-10 1996-04-10 Derivados de camptotecina y su utilizacion como agente antitumoral.

Country Status (13)

Country Link
US (2) US6504029B1 (es)
EP (1) EP0737686B1 (es)
KR (1) KR100400941B1 (es)
CN (1) CN1050131C (es)
AT (1) ATE181919T1 (es)
CA (1) CA2173671A1 (es)
DE (1) DE69603117T2 (es)
DK (1) DK0737686T3 (es)
EA (1) EA000036B1 (es)
ES (1) ES2136338T3 (es)
GR (1) GR3031400T3 (es)
NO (1) NO314085B1 (es)
TW (1) TW382630B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60124387T2 (de) 2000-02-28 2007-10-11 Pfizer Enterprises Sarl. Synergistische pharmazeutische Zusammensetzungen zur Behandlung von kolorektalem Krebs
US6548488B2 (en) 2000-03-17 2003-04-15 Aventis Pharma S.A. Composition comprising camptothecin or a camptothecin derivative and an alkylating agent for the treatment of cancer
US6545010B2 (en) 2000-03-17 2003-04-08 Aventis Pharma S.A. Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer
AR030207A1 (es) * 2000-04-07 2003-08-13 Daiichi Seiyaku Co Composicion farmaceutica que contiene un derivado de camptotecina y procedimiento de preparacion de la misma
US6486320B2 (en) 2000-09-15 2002-11-26 Aventis Pharma S.A. Preparation of camptothecin and of its derivatives
AU1602902A (en) 2000-10-27 2002-05-06 Aventis Pharma Sa A combination comprising camptothecin and a stilbene derivative for the treatment of cancer
US20090104254A1 (en) 2004-12-22 2009-04-23 Rutgers, The State University Of New Jersey Controlled Release Hydrogels
WO2007113687A2 (en) 2006-03-30 2007-10-11 Diatos S.A. Camptothecin-cell penetrating peptide conjugates and pharmaceutical compositions containing the same
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
AR074897A1 (es) 2008-12-23 2011-02-23 Pharmasset Inc Fosforamidatos de nucleosidos
WO2010075554A1 (en) 2008-12-23 2010-07-01 Pharmasset, Inc. Synthesis of purine nucleosides
WO2010075517A2 (en) 2008-12-23 2010-07-01 Pharmasset, Inc. Nucleoside analogs
RS54368B1 (sr) 2010-03-31 2016-04-28 Gilead Pharmasset Llc Kristalni (s)-izopropil 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-diokso-3,4-dihidropirimidin-1-(2h)-il)-4-fluoro-3-hidroksi-4-metiltetrahidrofuran-2-il)metoksi)(fenoksi)fosforil)amino)propanoat
US20140086975A1 (en) 2010-10-15 2014-03-27 Rutgers, The State University Of New Jersey Hydrogel formulation for dermal and ocular delivery
RS60000B1 (sr) 2012-10-11 2020-04-30 Daiichi Sankyo Co Ltd Veznici za antitelo-lek konjugate
EP2910573B1 (en) 2012-10-19 2020-02-19 Daiichi Sankyo Company, Limited Antibody-drug conjugate produced by binding through linker having hydrophilic structure
SMT202500227T1 (it) 2013-12-25 2025-09-12 Daiichi Sankyo Co Ltd Metodo per produrre un coniugato anticorpo anti-trop2-farmaco
HRP20241783T1 (hr) 2014-01-31 2025-02-28 Daiichi Sankyo Company, Limited Anti-her2 antitijelo-lijek konjugat
CN111228511B (zh) 2014-04-10 2024-06-18 第一三共株式会社 抗her3抗体-药物偶联物
EP3130608B1 (en) 2014-04-10 2019-09-04 Daiichi Sankyo Co., Ltd. (anti-her2 antibody)-drug conjugate
JP6787890B2 (ja) 2015-06-29 2020-11-18 第一三共株式会社 抗体−薬物コンジュゲートの選択的製造方法
TWI862473B (zh) 2016-12-12 2024-11-21 日商第一三共股份有限公司 抗體-藥物結合物與免疫檢查點抑制劑之組合、以及醫藥組成物之用途
TWI780104B (zh) 2017-01-17 2022-10-11 日商第一三共股份有限公司 抗ｇｐｒ２０抗體及抗ｇｐｒ２０抗體-藥物結合物、以及其製造方法及用途
TWI855528B (zh) 2017-05-15 2024-09-11 日商第一三共股份有限公司 抗體-藥物結合物之製造方法
US11318212B2 (en) 2017-08-31 2022-05-03 Daiichi Sankyo Company, Limited Method for producing antibody-drug conjugate
AU2018327171B2 (en) 2017-08-31 2023-03-09 Daiichi Sankyo Company, Limited Improved method for producing antibody-drug conjugate
SMT202300227T1 (it) 2018-05-18 2023-09-06 Glycotope Gmbh Anticorpo anti-muc1
IL280296B2 (en) 2018-07-27 2025-03-01 Daiichi Sankyo Co Ltd Drug recognition protein of an antibody-drug conjugate
AU2019315177A1 (en) 2018-07-31 2021-02-25 Daiichi Sankyo Company, Limited Treatment of metastatic brain tumor by administration of antibody-drug conjugate
WO2020063676A1 (zh) 2018-09-26 2020-04-02 江苏恒瑞医药股份有限公司 依喜替康类似物的配体-药物偶联物及其制备方法和应用
US12377163B2 (en) 2018-09-30 2025-08-05 Jiangsu Hansoh Pharmaceutical Group Co., Ltd Anti-B7H3 antibody-exatecan analog conjugate and medicinal use thereof
HRP20221280T1 (hr) 2019-03-29 2022-12-23 Medimmune Limited Spojevi i njihovi konjugati
PE20220563A1 (es) 2019-07-10 2022-04-13 Cybrexa 2 Inc Conjugados peptidicos de citotoxinas como terapeuticos
MX2022000450A (es) 2019-07-10 2022-04-25 Cybrexa 3 Inc Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos.
AU2020402006A1 (en) 2019-12-12 2022-07-07 Jiangsu Hengrui Medicine Co., Ltd. Anti-claudin antibody-drug conjugate and pharmaceutical use thereof
KR20220130717A (ko) 2020-01-22 2022-09-27 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 항-trop-2 항체-엑사테칸 유사체 접합체 및 이의 의학적 용도
BR112022019073A2 (pt) 2020-03-25 2022-11-08 Jiangsu Hengrui Pharmaceuticals Co Ltd Composição farmacêutica que compreende conjugado anticorpo-fármaco e uso da mesma
TWI888517B (zh) 2020-03-25 2025-07-01 大陸商江蘇恆瑞醫藥股份有限公司 抗ｐｓｍａ抗體-依喜替康類似物偶聯物及其醫藥用途
US20230241242A1 (en) 2020-03-25 2023-08-03 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Preparation method for antibody medicament conjugate
CN117940432B (zh) * 2021-09-01 2025-12-23 上海弼领生物技术有限公司 一种喜树碱类化合物、其制备方法和用途
CN117986268A (zh) * 2022-10-28 2024-05-07 安徽皓元药业有限公司 一种依喜替康甲磺酸盐的晶型及其制备方法
WO2024149193A1 (zh) * 2023-01-09 2024-07-18 四川科伦博泰生物医药股份有限公司 含氮稠环化合物的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6087746A (ja) * 1983-10-17 1985-05-17 Hakubakumai Kk 即席麺ないしは焼そば用蒸し麺の製造方法
US4939255A (en) * 1987-06-24 1990-07-03 Daiichi Pharmaceutical Co., Ltd. Hexa-cyclic camptothecin derivatives
US4943579A (en) * 1987-10-06 1990-07-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble prodrugs of camptothecin
US5004758A (en) * 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
US5658920A (en) * 1991-01-16 1997-08-19 Daiichi Pharmaceutical Co., Ltd. Substituted 1H,12H-benz-[DE]pyrano[3',4':6,7] indolizino[1,2-B]quinoline-10,13(9H,15H)-dione compound
JP3008226B2 (ja) * 1991-01-16 2000-02-14 第一製薬株式会社 六環性化合物
JP3359955B2 (ja) * 1992-07-16 2002-12-24 第一製薬株式会社 抗腫瘍剤
IS4152A (is) * 1993-04-29 1994-10-30 Glaxo Inc. Vatnsuppleysanlegar Camptothecin afleiður og aðferð til framleiðslu þeirra
GB9319944D0 (en) * 1993-09-28 1993-11-17 Erba Carlo Spa Process for the preparation of 9-amino camptothecin

Also Published As

Publication number Publication date
US6552197B2 (en) 2003-04-22
DE69603117T2 (de) 1999-10-28
NO961405L (no) 1996-10-11
EP0737686A1 (en) 1996-10-16
KR100400941B1 (ko) 2003-12-24
KR960037682A (ko) 1996-11-19
DE69603117D1 (de) 1999-08-12
CN1050131C (zh) 2000-03-08
EP0737686B1 (en) 1999-07-07
US6504029B1 (en) 2003-01-07
US20010034446A1 (en) 2001-10-25
CN1133290A (zh) 1996-10-16
CA2173671A1 (en) 1996-10-11
NO961405D0 (no) 1996-04-09
EA199600018A3 (ru) 1997-03-31
AU692078B2 (en) 1998-05-28
AU5056696A (en) 1996-10-24
TW382630B (en) 2000-02-21
GR3031400T3 (en) 2000-01-31
EA199600018A2 (ru) 1996-10-01
DK0737686T3 (da) 1999-11-22
ATE181919T1 (de) 1999-07-15
NO314085B1 (no) 2003-01-27
EA000036B1 (ru) 1998-02-26

Similar Documents

Publication Publication Date Title
ES2136338T3 (es) Derivados de camptotecina y su utilizacion como agente antitumoral.
ES8106721A1 (es) Un metodo para la preparacion de derivados de ftalimidina
FR2391210A1 (fr) Derives d'acides quinoleinecarboxyliques et leur utilisation comme agents antibacteriens
UA11192A (uk) Спосіб отримаhhя похідhих заміщеhого
FR2383907A1 (fr) Procede de preparation de derives de l'acide acetique et derives obtenus par ce procede
NO882588L (no) Fremgangsmaate ved fremstilling av substituerte inololinonderivater.
FR2372817A1 (fr) Derives d'acides thiazolidinecarboxyliques et d'acides apparentes, utiles comme agents anti-hypertension
PE31091A1 (es) Compuestos fungicidas oxazolidinones y metodo de preparacion
BR0213814A (pt) Processos para a fabricação de 3-hidroxi-n, 1,6-trialquil-4-oxo-1, 4-diidro piridino-2-carboxamida
FR2394522A1 (fr) Nouveaux derives d'acides (s-phenenyl tris(carbonylimino))-5,5',5''tri-benzene-carboxyliques utiles notamment comme inhibiteurs du complement, et leur procede de preparation
UA7046A1 (uk) Спосіб одержання похідних циклопропана
NO873248D0 (no) Fremgangsmaate for fremstilling av kinolincarboxylsyrer.
ATE10735T1 (de) Verfahren zur herstellung von chinonderivaten.
KR910002865A (ko) 피라노벤즈옥사디아졸 화합물 및 그 광학적 분할방법
RO92245A (ro) Procedeu pentru prepararea unor derivati de 1,6-naftiridina
DE69809888D1 (de) Verfahren zur Herstellung von alpha-Aminoketonen
ZA875821B (en) Diselenobis benzoic acid amides of primary heterocyclic amines,process for producing the same and pharmaceutical compounds comprising the same
DE50009219D1 (de) Verfahren zur herstellung von estern
ES2096375T3 (es) Procedimiento de obtencion de beta-yonona.
FR2383920A1 (fr) Procede de preparation d'un derive d'acetonitrile et derive obtenu par ce procede
KR880701226A (ko) 1-치환(s)-및(r)-2- 아미노메틸롤리딘 및 그의 중간체의 효과적인 입체보전 합성법
PL326563A1 (en) Method of obtaining derivatives of methoxyiminophenyglyoxalic acid
ATE104975T1 (de) Verfahren zur herstellung von imidazol-derivaten.
DK342383A (da) Fremgangsmaade til fremstilling af 4-amino-5-dialkoxymethylpyrimidinderivater
SE8503811L (sv) Nytt forfarande for framstellning av en aminolakton

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 737686

Country of ref document: ES